Challenges to success in heart failure: Cardiac cell therapies in patients with heart diseases

Journal of Cardiology

Volumn 68, Issue 5, 2016, Pages 361-367

  Oh, Hidemasa ^a   Ito, Hiroshi ^b   Sano, Shunji ^b  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cardiac progenitors; Cell therapy; Congenital heart disease; Dilated cardiomyopathy; Myocardial infarction

Indexed keywords

ADULT DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; CARDIAC MUSCLE CELL; CARDIAC STEM CELL; CELL THERAPY; CONGENITAL HEART DISEASE; HEART DISEASE; HEART FAILURE; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PALLIATIVE THERAPY; PEDIATRICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATIVE MEDICINE; REVIEW; STEM CELL SELF-RENEWAL; ANIMAL; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL (TOPIC); HEART DISEASES; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; HEART DISEASES; HUMANS; MYOCYTES, CARDIAC; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 84995449847     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2016.04.010     Document Type: Review

References (78)

1. [1] Ziaeian, B., Fonarow, G.C., Epidemiology and aetiology of heart failure. Nat Rev Cardiol, 2016.
2. [2] Ptaszek, L.M., Mansour, M., Ruskin, J.N., Chien, K.R., Towards regenerative therapy for cardiac disease. Lancet 379 (2012), 933–942.
3. [3] Rosenzweig, A., Cardiac cell therapy – mixed results from mixed cells. N Engl J Med 355 (2006), 1274–1277.
4. [4] Li, T.S., Cheng, K., Malliaras, K., Smith, R.R., Zhang, Y., Sun, B., Matsushita, N., Blusztajn, A., Terrovitis, J., Kusuoka, H., Marban, L., Marban, E., Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 59 (2012), 942–953.
5. [5] Lian, X., Zhang, J., Azarin, S.M., Zhu, K., Hazeltine, L.B., Bao, X., Hsiao, C., Kamp, T.J., Palecek, S.P., Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc 8 (2013), 162–175.
6. [6] Hirt, M.N., Hansen, A., Eschenhagen, T., Cardiac tissue engineering: state of the art. Circ Res 114 (2014), 354–367.
7. [7] Sadahiro, T., Yamanaka, S., Ieda, M., Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications. Circ Res 116 (2015), 1378–1391.
8. [8] Eulalio, A., Mano, M., Dal Ferro, M., Zentilin, L., Sinagra, G., Zacchigna, S., Giacca, M., Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492 (2012), 376–381.
9. [9] Sahoo, S., Losordo, D.W., Exosomes and cardiac repair after myocardial infarction. Circ Res 114 (2014), 333–344.
10. [10] Tse, H.F., Kwong, Y.L., Chan, J.K., Lo, G., Ho, C.L., Lau, C.P., Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361 (2003), 47–49.
11. [11] Wollert, K.C., Meyer, G.P., Lotz, J., Ringes-Lichtenberg, S., Lippolt, P., Breidenbach, C., Fichtner, S., Korte, T., Hornig, B., Messinger, D., Arseniev, L., Hertenstein, B., Ganser, A., Drexler, H., Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364 (2004), 141–148.
12. [12] Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Holschermann, H., Yu, J., Corti, R., Mathey, D.G., Hamm, C.W., Suselbeck, T., Assmus, B., Tonn, T., Dimmeler, S., Zeiher, A.M., Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355 (2006), 1210–1221.
13. [13] Assmus, B., Honold, J., Schachinger, V., Britten, M.B., Fischer-Rasokat, U., Lehmann, R., Teupe, C., Pistorius, K., Martin, H., Abolmaali, N.D., Tonn, T., Dimmeler, S., Zeiher, A.M., Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355 (2006), 1222–1232.
14. [14] Janssens, S., Dubois, C., Bogaert, J., Theunissen, K., Deroose, C., Desmet, W., Kalantzi, M., Herbots, L., Sinnaeve, P., Dens, J., Maertens, J., Rademakers, F., Dymarkowski, S., Gheysens, O., Van Cleemput, J., et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367 (2006), 113–121.
15. [15] Meyer, G.P., Wollert, K.C., Lotz, J., Steffens, J., Lippolt, P., Fichtner, S., Hecker, H., Schaefer, A., Arseniev, L., Hertenstein, B., Ganser, A., Drexler, H., Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113 (2006), 1287–1294.
16. [16] Traverse, J.H., Henry, T.D., Ellis, S.G., Pepine, C.J., Willerson, J.T., Zhao, D.X., Forder, J.R., Byrne, B.J., Hatzopoulos, A.K., Penn, M.S., Perin, E.C., Baran, K.W., Chambers, J., Lambert, C., Raveendran, G., et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 306 (2011), 2110–2119.
17. [17] Traverse, J.H., Henry, T.D., Pepine, C.J., Willerson, J.T., Zhao, D.X., Ellis, S.G., Forder, J.R., Anderson, R.D., Hatzopoulos, A.K., Penn, M.S., Perin, E.C., Chambers, J., Baran, K.W., Raveendran, G., Lambert, C., et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 308 (2012), 2380–2389.
18. [18] Surder, D., Manka, R., Lo Cicero, V., Moccetti, T., Rufibach, K., Soncin, S., Turchetto, L., Radrizzani, M., Astori, G., Schwitter, J., Erne, P., Zuber, M., Auf der Maur, C., Jamshidi, P., Gaemperli, O., et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation 127 (2013), 1968–1979.
19. [19] Tendera, M., Wojakowski, W., Ruzyllo, W., Chojnowska, L., Kepka, C., Tracz, W., Musialek, P., Piwowarska, W., Nessler, J., Buszman, P., Grajek, S., Breborowicz, P., Majka, M., Ratajczak, M.Z., Intracoronary infusion of bone marrow-derived selected CD34+ CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 30 (2009), 1313–1321.
20. [20] Hirsch, A., Nijveldt, R., van der Vleuten, P.A., Tijssen, J.G., van der Giessen, W.J., Tio, R.A., Waltenberger, J., ten Berg, J.M., Doevendans, P.A., Aengevaeren, W.R., Zwaginga, J.J., Biemond, B.J., van Rossum, A.C., Piek, J.J., Zijlstra, F., Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 32 (2011), 1736–1747.
21. [21] Donndorf, P., Kundt, G., Kaminski, A., Yerebakan, C., Liebold, A., Steinhoff, G., Glass, A., Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: a meta-analysis. J Thorac Cardiovasc Surg 142 (2011), 911–920.
22. [22] Jeevanantham, V., Butler, M., Saad, A., Abdel-Latif, A., Zuba-Surma, E.K., Dawn, B., Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 126 (2012), 551–568.
23. [23] Zimmet, H., Porapakkham, P., Sata, Y., Haas, S.J., Itescu, S., Forbes, A., Krum, H., Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail 14 (2012), 91–105.
24. [24] Delewi, R., Hirsch, A., Tijssen, J.G., Schachinger, V., Wojakowski, W., Roncalli, J., Aakhus, S., Erbs, S., Assmus, B., Tendera, M., Goekmen Turan, R., Corti, R., Henry, T., Lemarchand, P., Lunde, K., et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J 35 (2014), 989–998.
25. [25] Afzal, M.R., Samanta, A., Shah, Z.I., Jeevanantham, V., Abdel-Latif, A., Zuba-Surma, E.K., Dawn, B., Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res 117 (2015), 558–575.
26. [26] Fisher, S.A., Doree, C., Mathur, A., Martin-Rendon, E., Meta-analysis of cell therapy trials for patients with heart failure. Circ Res 116 (2015), 1361–1377.
27. [27] Khan, A.R., Farid, T.A., Pathan, A., Tripathi, A., Ghafghazi, S., Wysoczynski, M., Bolli, R., Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis. Circ Res 118 (2016), 984–993.
28. [28] de Jong, R., Houtgraaf, J.H., Samiei, S., Boersma, E., Duckers, H.J., Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. Circ Cardiovasc Intervent 7 (2014), 156–167.
29. [29] Gyongyosi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marban, E., Assmus, B., Henry, T.D., Traverse, J.H., Moye, L.A., Surder, D., Corti, R., Huikuri, H., Miettinen, J., et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 116 (2015), 1346–1360.
30. [30] Nowbar, A.N., Mielewczik, M., Karavassilis, M., Dehbi, H.M., Shun-Shin, M.J., Jones, S., Howard, J.P., Cole, G.D., Francis, D.P., Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ (Clin Res Ed), 348, 2014, g2688.
31. [31] Heldman, A.W., DiFede, D.L., Fishman, J.E., Zambrano, J.P., Trachtenberg, B.H., Karantalis, V., Mushtaq, M., Williams, A.R., Suncion, V.Y., McNiece, I.K., Ghersin, E., Soto, V., Lopera, G., Miki, R., Willens, H., et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311 (2014), 62–73.
32. [32] Houtgraaf, J.H., den Dekker, W.K., van Dalen, B.M., Springeling, T., de Jong, R., van Geuns, R.J., Geleijnse, M.L., Fernandez-Aviles, F., Zijlsta, F., Serruys, P.W., Duckers, H.J., First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 59 (2012), 539–540.
33. [33] Perin, E.C., Sanz-Ruiz, R., Sanchez, P.L., Lasso, J., Perez-Cano, R., Alonso-Farto, J.C., Perez-David, E., Fernandez-Santos, M.E., Serruys, P.W., Duckers, H.J., Kastrup, J., Chamuleau, S., Zheng, Y., Silva, G.V., Willerson, J.T., et al. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J 168 (2014), 88–9500.
34. [34] Hierlihy, A.M., Seale, P., Lobe, C.G., Rudnicki, M.A., Megeney, L.A., The post-natal heart contains a myocardial stem cell population. FEBS Lett 530 (2002), 239–243.
35. [35] Oh, H., Bradfute, S.B., Gallardo, T.D., Nakamura, T., Gaussin, V., Mishina, Y., Pocius, J., Michael, L.H., Behringer, R.R., Garry, D.J., Entman, M.L., Schneider, M.D., Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A 100 (2003), 12313–12318.
36. [36] Beltrami, A.P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., Kasahara, H., Rota, M., Musso, E., Urbanek, K., Leri, A., Kajstura, J., Nadal-Ginard, B., Anversa, P., Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114 (2003), 763–776.
37. [37] Messina, E., De Angelis, L., Frati, G., Morrone, S., Chimenti, S., Fiordaliso, F., Salio, M., Battaglia, M., Latronico, M.V., Coletta, M., Vivarelli, E., Frati, L., Cossu, G., Giacomello, A., Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95 (2004), 911–921.
38. [38] Laugwitz, K.L., Moretti, A., Lam, J., Gruber, P., Chen, Y., Woodard, S., Lin, L.Z., Cai, C.L., Lu, M.M., Reth, M., Platoshyn, O., Yuan, J.X., Evans, S., Chien, K.R., Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433 (2005), 647–653.
39. [39] Zwetsloot, P.P., Vegh, A.M., Jansen Of Lorkeers, S.J., van Hout, G.P., Currie, G.L., Sena, E.S., Gremmels, H., Buikema, J.W., Goumans, M.J., Macleod, M.R., Doevendans, P.A., Chamuleau, S.A., Sluijter, J.P., Cardiac stem cell treatment in myocardial infarction: a systematic review and meta-analysis of preclinical studies. Circ Res, 2016.
40. [40] Takehara, N., Tsutsumi, Y., Tateishi, K., Ogata, T., Tanaka, H., Ueyama, T., Takahashi, T., Takamatsu, T., Fukushima, M., Komeda, M., Yamagishi, M., Yaku, H., Tabata, Y., Matsubara, H., Oh, H., Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol 52 (2008), 1858–1865.
41. [41] Leor, J., Tuvia, S., Guetta, V., Manczur, F., Castel, D., Willenz, U., Petnehazy, O., Landa, N., Feinberg, M.S., Konen, E., Goitein, O., Tsur-Gang, O., Shaul, M., Klapper, L., Cohen, S., Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J Am Coll Cardiol 54 (2009), 1014–1023.
42. [42] Bolli, R., Tang, X.L., Sanganalmath, S.K., Rimoldi, O., Mosna, F., Abdel-Latif, A., Jneid, H., Rota, M., Leri, A., Kajstura, J., Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 128 (2013), 122–131.
43. [43] Kubo, H., Jaleel, N., Kumarapeli, A., Berretta, R.M., Bratinov, G., Shan, X., Wang, H., Houser, S.R., Margulies, K.B., Increased cardiac myocyte progenitors in failing human hearts. Circulation 118 (2008), 649–657.
44. [44] Bearzi, C., Rota, M., Hosoda, T., Tillmanns, J., Nascimbene, A., De Angelis, A., Yasuzawa-Amano, S., Trofimova, I., Siggins, R.W., Lecapitaine, N., Cascapera, S., Beltrami, A.P., D'Alessandro, D.A., Zias, E., Quaini, F., et al. Human cardiac stem cells. Proc Natl Acad Sci U S A 104 (2007), 14068–14073.
45. [45] Tallini, Y.N., Greene, K.S., Craven, M., Spealman, A., Breitbach, M., Smith, J., Fisher, P.J., Steffey, M., Hesse, M., Doran, R.M., Woods, A., Singh, B., Yen, A., Fleischmann, B.K., Kotlikoff, M.I., c-kit expression identifies cardiovascular precursors in the neonatal heart. Proc Natl Acad Sci U S A 106 (2009), 1808–1813.
46. [46] Zaruba, M.M., Soonpaa, M., Reuter, S., Field, L.J., Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation 121 (2010), 1992–2000.
47. [47] van Berlo, J.H., Kanisicak, O., Maillet, M., Vagnozzi, R.J., Karch, J., Lin, S.C., Middleton, R.C., Marban, E., Molkentin, J.D., c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509 (2014), 337–341.
48. [48] Sultana, N., Zhang, L., Yan, J., Chen, J., Cai, W., Razzaque, S., Jeong, D., Sheng, W., Bu, L., Xu, M., Huang, G.Y., Hajjar, R.J., Zhou, B., Moon, A., Cai, C.L., Resident c-kit(+) cells in the heart are not cardiac stem cells. Nat Commun, 6, 2015, 8701.
49. [49] Bolli, R., Chugh, A.R., D'Amario, D., Loughran, J.H., Stoddard, M.F., Ikram, S., Beache, G.M., Wagner, S.G., Leri, A., Hosoda, T., Sanada, F., Elmore, J.B., Goichberg, P., Cappetta, D., Solankhi, N.K., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378 (2011), 1847–1857.
50. [50] Chugh, A.R., Beache, G.M., Loughran, J.H., Mewton, N., Elmore, J.B., Kajstura, J., Pappas, P., Tatooles, A., Stoddard, M.F., Lima, J.A., Slaughter, M.S., Anversa, P., Bolli, R., Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 126 (2012), S54–S64.
51. [51] Patella, V., Marino, I., Arbustini, E., Lamparter-Schummert, B., Verga, L., Adt, M., Marone, G., Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 97 (1998), 971–978.
52. [52] Smith, R.R., Barile, L., Cho, H.C., Leppo, M.K., Hare, J.M., Messina, E., Giacomello, A., Abraham, M.R., Marban, E., Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115 (2007), 896–908.
53. [53] Johnston, P.V., Sasano, T., Mills, K., Evers, R., Lee, S.T., Smith, R.R., Lardo, A.C., Lai, S., Steenbergen, C., Gerstenblith, G., Lange, R., Marban, E., Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 120 (2009), 1075–1083 [7 p. following 83].
54. [54] Lee, S.T., White, A.J., Matsushita, S., Malliaras, K., Steenbergen, C., Zhang, Y., Li, T.S., Terrovitis, J., Yee, K., Simsir, S., Makkar, R., Marban, E., Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 57 (2011), 455–465.
55. [55] Makkar, R.R., Smith, R.R., Cheng, K., Malliaras, K., Thomson, L.E., Berman, D., Czer, L.S., Marban, L., Mendizabal, A., Johnston, P.V., Russell, S.D., Schuleri, K.H., Lardo, A.C., Gerstenblith, G., Marban, E., Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379 (2012), 895–904.
56. [56] Malliaras, K., Makkar, R.R., Smith, R.R., Cheng, K., Wu, E., Bonow, R.O., Marban, L., Mendizabal, A., Cingolani, E., Johnston, P.V., Gerstenblith, G., Schuleri, K.H., Lardo, A.C., Marban, E., Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 63 (2014), 110–122.
57. [57] Seth, S., Narang, R., Bhargava, B., Ray, R., Mohanty, S., Gulati, G., Kumar, L., Reddy, K.S., Venugopal, P., Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial. J Am Coll Cardiol 48 (2006), 2350–2351.
58. [58] Hamshere, S., Arnous, S., Choudhury, T., Choudry, F., Mozid, A., Yeo, C., Barrett, C., Saunders, N., Gulati, A., Knight, C., Locca, D., Davies, C., Cowie, M.R., Prasad, S., Parmar, M., et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. Eur Heart J 36 (2015), 3061–3069.
59. [59] Tseliou, E., Kanazawa, H., Dawkins, J., Gallet, R., Kreke, M., Smith, R., Middleton, R., Valle, J., Marban, L., Kar, S., Makkar, R., Marban, E., Widespread myocardial delivery of heart-derived stem cells by nonocclusive triple-vessel intracoronary infusion in porcine ischemic cardiomyopathy: superior attenuation of adverse remodeling documented by magnetic resonance imaging and histology. PLoS ONE, 11, 2016, e0144523.
60. [60] Tateishi, K., Ashihara, E., Honsho, S., Takehara, N., Nomura, T., Takahashi, T., Ueyama, T., Yamagishi, M., Yaku, H., Matsubara, H., Oh, H., Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun 352 (2007), 635–641.
61. [61] Malliaras, K., Li, T.S., Luthringer, D., Terrovitis, J., Cheng, K., Chakravarty, T., Galang, G., Zhang, Y., Schoenhoff, F., Van Eyk, J., Marban, L., Marban, E., Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125 (2012), 100–112.
62. [62] Jansen Of Lorkeers, S.J., Eding, J.E., Vesterinen, H.M., van der Spoel, T.I., Sena, E.S., Duckers, H.J., Doevendans, P.A., Macleod, M.R., Chamuleau, S.A., Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res 116 (2015), 80–86.
63. [63] Hare, J.M., Fishman, J.E., Gerstenblith, G., DiFede Velazquez, D.L., Zambrano, J.P., Suncion, V.Y., Tracy, M., Ghersin, E., Johnston, P.V., Brinker, J.A., Breton, E., Davis-Sproul, J., Schulman, I.H., Byrnes, J., Mendizabal, A.M., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308 (2012), 2369–2379.
64. [64] Karantalis, V., Suncion-Loescher, V.Y., Bagno, L., Golpanian, S., Wolf, A., Sanina, C., Premer, C., Kanelidis, A.J., McCall, F., Wang, B., Balkan, W., Rodriguez, J., Rosado, M., Morales, A., Hatzistergos, K., et al. Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy. J Am Coll Cardiol 66 (2015), 1990–1999.
65. [65] Davies, B., Elwood, N.J., Li, S., Cullinane, F., Edwards, G.A., Newgreen, D.F., Brizard, C.P., Human cord blood stem cells enhance neonatal right ventricular function in an ovine model of right ventricular training. Ann Thorac Surg 89 (2010), 585–593 93 e1–4.
66. [66] Rupp, S., Bauer, J., Tonn, T., Schachinger, V., Dimmeler, S., Zeiher, A.M., Schranz, D., Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy. Pediatr Transplant 13 (2009), 620–623.
67. [67] Rupp, S., Zeiher, A.M., Dimmeler, S., Tonn, T., Bauer, J., Jux, C., Akintuerk, H., Schranz, D., A regenerative strategy for heart failure in hypoplastic left heart syndrome: intracoronary administration of autologous bone marrow-derived progenitor cells. J Heart Lung Transpl 29 (2010), 574–577.
68. [68] Rupp, S., Jux, C., Bonig, H., Bauer, J., Tonn, T., Seifried, E., Dimmeler, S., Zeiher, A.M., Schranz, D., Intracoronary bone marrow cell application for terminal heart failure in children. Cardiol Young 22 (2012), 558–563.
69. [69] Bergmane, I., Lacis, A., Lubaua, I., Jakobsons, E., Erglis, A., Follow-up of the patients after stem cell transplantation for pediatric dilated cardiomyopathy. Pediatr Transplant 17 (2013), 266–270.
70. [70] Simpson, D.L., Mishra, R., Sharma, S., Goh, S.K., Deshmukh, S., Kaushal, S., A strong regenerative ability of cardiac stem cells derived from neonatal hearts. Circulation 126 (2012), S46–S53.
71. [71] Ishigami, S., Ohtsuki, S., Tarui, S., Ousaka, D., Eitoku, T., Kondo, M., Okuyama, M., Kobayashi, J., Baba, K., Arai, S., Kawabata, T., Yoshizumi, K., Tateishi, A., Kuroko, Y., Iwasaki, T., et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res 116 (2015), 653–664.
72. [72] Tarui, S., Ishigami, S., Ousaka, D., Kasahara, S., Ohtsuki, S., Sano, S., Oh, H., Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg 150 (2015), 1198–1207 208 e1–2.
73. [73] Burkhart, H.M., Qureshi, M.Y., Peral, S.C., O'Leary, P.W., Olson, T.M., Cetta, F., Nelson, T.J., Regenerative therapy for hypoplastic left heart syndrome: first report of intraoperative intramyocardial injection of autologous umbilical-cord blood-derived cells. J Thorac Cardiovasc Surg 149 (2015), e35–e37.
74. [74] Cantero Peral, S., Burkhart, H.M., Oommen, S., Yamada, S., Nyberg, S.L., Li, X., O'Leary, P.W., Terzic, A., Cannon, B.C., Nelson, T.J., Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system. Stem Cells Transl Med 4 (2015), 195–206.
75. [75] Guyette, J.P., Charest, J.M., Mills, R.W., Jank, B.J., Moser, P.T., Gilpin, S.E., Gershlak, J.R., Okamoto, T., Gonzalez, G., Milan, D.J., Gaudette, G.R., Ott, H.C., Bioengineering human myocardium on native extracellular matrix. Circ Res 118 (2016), 56–72.
76. [76] Hu, Y.F., Dawkins, J.F., Cho, H.C., Marban, E., Cingolani, E., Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci Transl Med, 6, 2014, 245ra94.
77. [77] Smart, N., Bollini, S., Dube, K.N., Vieira, J.M., Zhou, B., Davidson, S., Yellon, D., Riegler, J., Price, A.N., Lythgoe, M.F., Pu, W.T., Riley, P.R., De novo cardiomyocytes from within the activated adult heart after injury. Nature 474 (2011), 640–644.
78. [78] Wei, K., Serpooshan, V., Hurtado, C., Diez-Cunado, M., Zhao, M., Maruyama, S., Zhu, W., Fajardo, G., Noseda, M., Nakamura, K., Tian, X., Liu, Q., Wang, A., Matsuura, Y., Bushway, P., et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 525 (2015), 479–485.